Intelligence Briefing · ~4 min read
Emerging Competitive Dynamics in Cardiovascular Generic Therapies Following Recent FDA Approvals
Cardiovascular · Beta-blocker
Type
Strategic BriefingGenerated
Jul 23, 2026
Confidence
Moderate Confidence · 72%
Evidence
11 items
Sources
11
Key Takeaways
Leadership-ready summary — read in 4 minutes.
- Portfolio teams should assess the impact of this generic entry on pricing and market share for existing propranolol products. The strongest clinical anchor is Study of Antihypertensive Treatment and Cardiovascular Risk in Chinese Prehypertensive Population (ClinicalTrials.gov), moderate corpus alignment. In Cardiovascular · Beta-blocker, 8 regulatory and 2 competitive items passed relevance filtering for Propranolol Hydrochloride.
- Monitor market entry timelines and pricing strategies from new entrants like PAI Holdings and Lupin Ltd.
- Watch for competitor responses to pricing pressures and potential shifts in market share dynamics.
Why It Matters
Strategic context for leadership and portfolio decision-making.
Portfolio teams should assess the impact of this generic entry on pricing and market share for existing propranolol products. The strongest clinical anchor is Study of Antihypertensive Treatment and Cardiovascular Risk in Chinese Prehypertensive Population (ClinicalTrials.gov), moderate corpus alignment. In Cardiovascular · Beta-blocker, 8 regulatory and 2 competitive items passed relevance filtering for Propranolol Hydrochloride.
Supporting Evidence
Evidence-backed items from the Humanexa intelligence graph.
FDA Grants Approval for Propranolol Hydrochloride ANDA219165
Cardiovascular · Beta-blocker
Source: Regulatory Approval
View evidenceLupin's ANDA078232 for Losartan Potassium Receives AP Status from FDA
Cardiovascular · Antihypertensive
Source: Regulatory Approval
View evidenceSandoz receives AP status for Irbesartan and Hydrochlorothiazide ANDA
Cardiovascular · Hypertension
Source: Regulatory Approval
View evidenceEzetimibe-atorvastatin SPC approved in China; economic value assessment needed
Cardiovascular · Hypercholesterolemia
Source: Regulatory Approval
View evidenceFDA Approves ANDA216272 for Norepinephrine Bitartrate by Nephron
Cardiovascular · Vasopressor
Source: Regulatory Approval
View evidenceFDA Grants Approval for Olmesartan Medoxomil and Hydrochlorothiazide ANDA206371
Cardiovascular · Hypertension
Source: Regulatory Approval
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- FDA Grants Approval for Propranolol Hydrochloride ANDA219165
Cardiovascular · Beta-blocker
- Lupin's ANDA078232 for Losartan Potassium Receives AP Status from FDA
Cardiovascular · Antihypertensive
- Sandoz receives AP status for Irbesartan and Hydrochlorothiazide ANDA
Cardiovascular · Hypertension
- Ezetimibe-atorvastatin SPC approved in China; economic value assessment needed
Cardiovascular · Hypercholesterolemia
- FDA Approves ANDA216272 for Norepinephrine Bitartrate by Nephron
Cardiovascular · Vasopressor
- FDA Grants Approval for Olmesartan Medoxomil and Hydrochlorothiazide ANDA206371
Cardiovascular · Hypertension
Insights
- Emerging Competitive Dynamics in Cardiovascular Generic Therapies Following Recent FDA Approvals
Cardiovascular · Beta-blocker